Is Organon and Co. (OGN) overvalued or fairly valued?

MarketChacha shows Organon and Co.'s valuation in context — a trailing P/E of about 6.5, a forward P/E of about 3.8, a price-to-book of about 3.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Organon and Co.'s reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.18×) from reported figures — education, not a rating.

What is Organon and Co.'s revenue?

Organon and Co. reported revenue of $6.2B for FY2025, with net profit of $187.0M, per official filings.

What is the share price of Organon and Co. (OGN)?

Organon and Co. last traded at $13.78 (+0.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Organon and Co.

OGN · NYSE · Healthcare · United States

Snapshot

TickerOGN

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUnited States

CEOMr. Joseph T. Morrissey Jr.

Employees10,000

HeadquartersJersey City, United States

Websitewww.organon.com

Filings tracked19

About Organon and Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Who owns it

Insiders0.5%
Institutions85.1%
Public & other14.4%

790 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.21%
Pentwater Capital Management Lp6.89%
Vanguard Portfolio Management LLC5.76%
Vanguard Capital Management LLC4.54%
State Street Corporation3.68%
Goldman Sachs Group Inc1.98%
UBS Group AG1.85%
Geode Capital Management, LLC1.83%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 13.3 points over the period — profitability is trending down.

Cash conversion1.18×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend16.3% → 3.0%

Margin has compressed by about 13.3 points over the period — profitability is trending down.

Return on equity24.9%

Latest ROE of 24.9% — capital is generating a healthy return.

Growth qualityrev -0% · PAT -57%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.6B · EPS 0.70

Est. earnings growth +11.5%

Next fiscal year

Rev $6.3B · EPS 3.62

Est. earnings growth +8.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$6.2B

Net margin

3.0%

ROE

24.9%

Revenue CAGR (2y)

-0.4%

Profit CAGR (2y)

-57.2%

EPS (FY2025)

0.72

Net profit (FY2025)

$187.0M

Ask MarketChacha about OGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$6.2B	$187.0M	0.72	3.0%	24.9%
FY2024	$6.4B	$864.0M	3.33	13.5%	183.1%
FY2023	$6.3B	$1.0B	3.99	16.3%	—

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.6B	$108.0M	0.40	6.9%
2026Q1	$1.5B	$146.0M	0.55	10.0%
2025Q3	$1.6B	$160.0M	0.61	10.0%
2025Q2	$1.6B	$145.0M	0.56	9.1%
2025Q1	$1.5B	$87.0M	0.33	5.8%
2024Q3	$1.6B	$359.0M	1.38	22.7%
2024Q2	$1.6B	$195.0M	0.75	12.1%
2024Q1	$1.6B	$201.0M	0.78	12.4%
2023Q3	$1.5B	$58.0M	0.23	3.8%
2023Q2	$1.6B	$242.0M	0.95	15.0%
2023Q1	$1.5B	$177.0M	0.69	11.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Exhibits
SEC7/31/2026material
10-Q filing
SEC7/31/2026
8-K — Shareholder vote results
SEC7/23/2026material
8-K — Other events
SEC7/17/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/11/2026material
10-Q filing
SEC5/4/2026
8-K — Results of operations, Exhibits
SEC4/30/2026material
8-K — Material agreement, Executive/director change, Reg FD disclosure, Exhibits
SEC4/27/2026material
10-K filing
SEC2/24/2026
8-K — Other events, Exhibits
SEC2/20/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/12/2026material

2025

10-K/A filing
SEC11/10/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/10/2025material
10-Q filing
SEC11/10/2025
8-K — Executive/director change
SEC11/7/2025material
8-K/A — Executive/director change, Exhibits
SEC10/30/2025
8-K — Executive/director change, Other events, Exhibits
SEC10/27/2025material
10-Q filing
SEC8/6/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/5/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.